TATA Health International Holdings Ltd.

TATA Health International Holdings Ltd.

HHKEX:1255
1.83
HKD
+0.01
(+0.27%)
315.70MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3.16
2.95
2.81
2.81
2.42
1.69
1.6
0.73
0.69
0.6
0.85
0.53
0.41
- -
Basic EPS, GAAP
0.09
0.05
-0.08
-0.17
-0.22
-0.01
-0.28
-0.71
-0.26
0.04
-0.13
-0.28
0.05
- -
Free Cash Flow per Basic Share
-0.12
-0.16
-0.52
0.02
0.33
0.08
0.05
-0.01
-0.03
0.05
0.14
-0.01
-0.09
- -
Dividend per Share
0.13
0.04
0.02
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
1.21
1.2
1.2
1.04
0.83
1.03
0.75
0.05
0.09
0.14
0.01
-0.27
-0.22
-0.22
Tangible Book Value per Share
1.21
1.2
1.2
1.04
0.83
0.78
0.59
0.05
0.09
0.14
0.01
-0.27
-0.22
-0.22
Basic Weighted Avg Shares
174
200
200
200
200
212
214
214
232
243
243
243
243
243
Sales/Revenue/Turnover
550
591
561
562
484
358
342
155
161
145
208
130
100
- -
Operating Margin (%)
4.95
2.19
-2.31
-5.98
-8.75
0.11
-10.78
-87.64
-35.84
-18.57
-14.52
-26.89
-22.87
- -
Depreciation Expense
12
14
13
11
8
4
32
24
14
12
14
16
12
- -
Net Income, GAAP
17
9
-16
-34
-43
-2
-61
-152
-61
10
-32
-68
13
- -
Effective Tax Rate (%)
21.26
25.46
- -
- -
- -
7.56
- -
- -
- -
21.88
- -
- -
4.55
- -
Profit Margin (%)
3
1.53
-2.92
-5.99
-8.98
-0.49
-17.83
-97.75
-37.76
6.65
-15.56
-52.7
13.38
- -
Working Capital
189
172
149
123
90
155
118
21
-38
-48
-46
-71
-71
-71
LT Debt
14
12
10
9
9
- -
43
36
14
9
14
7
3
3
Total Equity
241
239
240
208
166
237
173
10
14
19
-16
-56
-54
-54
Return on Invested Capital (%)
5.81
2.61
- -
- -
- -
2.44
- -
- -
- -
5.53
- -
- -
- -
- -
Return on Capital (%)
5.99
2.87
- -
- -
- -
-2.74
- -
- -
- -
26.37
- -
- -
-65.6
- -
Return on Common Equity (%)
8.45
3.76
-6.83
-15.03
-23.23
-0.91
-32.04
-177.93
-367.25
33.93
-182.61
- -
- -
- -

Capital Structure

HKD

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
29
12
23
LT Borrowings
- -
- -
- -
LT Finance Leases
7
2
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
243
243
243
Market Capitalization
- -
- -
316

Working Capital

HKD

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
112
104
71
Cash, Cash Equivalents & STI
23
22
18
Accounts Receivable, Net
5
40
4
Inventories
11
12
10
Total Current Liabilities
183
168
142
Payables & Accruals
- -
- -
- -
ST Debt
29
12
23
Deferred Revenue
- -
- -
- -

Growth Rates

HKD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.59%
25.62%
-3.1%
Free Cash Flow
150.89%
72.17%
484.24%
Net Income, GAAP
295.17%
-123.94%
-119.54%
Sales/Revenue/Turnover
-12.24%
-4.72%
-23.04%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
208
2024
- -
- -
130
2025
- -
- -
100

Semi-annual Earnings Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.13
2024
- -
- -
-0.28
2025
- -
- -
0.05

Semi-annual Dividends Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

CEO
Ming Qi Zhang
Full Time Employees
108
Sector
Retail trade
Industry
Apparel/Footwear retail
Address
Kwai Tak Industrial Centre Hong Kong Hong Kong
IPO Date
Jul 11, 2013
Business
TATA Health International Holdings Limited (1255.HK) is an investment holding company principally engaged in the trading of footwear products through wholesale and retail channels; the trading of healthcare products; the provision of financial services, including securities advisory, investment management, and corporate finance advisory; and online medical services, such as medical advisory and consultation. The company offers footwear under brands including Clarks, Josef Seibel, The Flexx, and Petite Jolie, operating approximately 31 retail outlets in Hong Kong and 4 in Macau as of mid-2025, with geographic operations spanning Hong Kong, Macau, Australia, Taiwan, Mainland China, Thailand, and Malaysia. Founded in 1974 and headquartered at Flat F-J, 11F, Kwai Tak Industrial Centre, 15-33 Kwai Tak Street, Kwai Chung, New Territories, Hong Kong, it operates as a subsidiary of Great Wall International Investment X Limited, targeting consumers seeking comfort footwear and related healthcare offerings in the consumer cyclical retail sector. In recent developments, the company completed disposals of the Shang Ying Retail Group and Shang Ying Capital Group in September 2025 to independent third parties, streamlining operations amid lost records and minimal activity in non-footwear segments; it also disposed of Shang Ying International Group in April 2025 and deconsolidated Shangying Internet Medical (Shanghai) Co. Limited following its bankruptcy liquidation proceedings initiated in 2024. These transactions contributed to a one-off gain of approximately HK$34.7 million in the six months ended June 2025, shifting focus to the core footwear business, which generated all revenue of HK$42.1 million during that period despite a 41.8% year-over-year decline due to economic uncertainty. Healthcare, financial services, and online medical segments remain stagnant with nil revenue, reflecting strategic exits and operational challenges including customs issues and funding constraints.